Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 22 references
Medicine
TL;DR
The report of a 66-year-old man with anti-GABA-B receptor encephalitis who presented with a witnessed generalized tonic–clonic seizure after a 2-day prodrome of nocturnal repetitive stereotyped behaviors retrospectively suspicious for subtle focal seizures with automatisms illustrates that new-onset refractory status epilepticus should prompt expedited autoimmune encephalitis evaluation and that structured oncologic surveillance remains necessary despite negative initial tumor screening.
Abstract
Anti-gamma-aminobutyric acid type B receptor (anti-GABA-B receptor) encephalitis is a rare autoimmune limbic encephalitis that frequently presents with seizures and may be associated with malignancy, most commonly small-cell lung cancer. We report a 66-year-old man with anti-GABA-B receptor encephalitis who presented with a witnessed generalized tonic–clonic seizure after a 2-day prodrome of nocturnal repetitive stereotyped behaviors retrospectively suspicious for subtle focal seizures with automatisms. Brain magnetic resonance imaging showed right-predominant hippocampal and multifocal cortical hyperintensities, and cerebrospinal fluid analysis showed mild pleocytosis and elevated protein with negative infectious testing. He deteriorated on hospital day 5 with refractory status epilepticus and hypoxemic respiratory failure requiring intubation and intensive care. Anti-GABA-B receptor antibodies were subsequently confirmed in both serum and cerebrospinal fluid. Initial malignancy evaluation included contrast-enhanced computed tomography of the chest, abdomen, and pelvis; serum tumor markers; and an onconeural antibody panel. No malignancy was detected. Treatment included intravenous methylprednisolone, 10 sessions of therapeutic plasma exchange, and multi-agent antiseizure therapy. He was extubated after approximately 2 weeks and discharged on hospital day 39 with a modified Rankin Scale score of 3. At 3 months, he was seizure-free, with a modified Rankin Scale score of 1, a Barthel Index of 95/100, and a Mini-Mental State Examination score of 30/30. This single uncontrolled case is hypothesis-generating and does not establish treatment efficacy, optimal plasma exchange duration, long-term prognosis, or definitive non-paraneoplastic status. It illustrates that new-onset refractory status epilepticus should prompt expedited autoimmune encephalitis evaluation and that structured oncologic surveillance remains necessary despite negative initial tumor screening.
A 59-year-old man developed olfactory dysfunction and behavioral changes that progressed to epilepsy. Brain magnetic resonance imaging (MRI) revealed multifocal cortico-subcortical T2-weighted fluid-attenuated inversion recovery (FLAIR) hyperintensities. Despite repeated plasmapheresis and immunotherapy with methylpred...
Takuma Mori, S. Nozuma, Takahiro Hobara et al.· Internal medicine· 0 citations
An 18-year-old man presented with 1 week of insomnia and headache, followed by erratic behavior, encephalopathy, seizures, and left-sided weakness. Brain MRI demonstrated cortical T2/FLAIR hyperintensity predominantly involving the right cerebral hemisphere, followed by progressive right-greater-than-left cortical volu...
Yoji Hoshina, O. Rapalino, J. Linnoila· The Neurohospitalist· 0 citations
Findings support the possibility that anti-mGluR1 encephalitis may, in rare instances, present with predominant brainstem involvement and testing for anti-mGluR1 antibodies may be considered in patients with otherwise unexplained subacute inflammatory brainstem syndromes.
The case of a 35-year-old man who presented with sudden-onset generalized tonic-clonic seizures highlights that FLAMES may be complicated by postictal purpura and rhabdomyolysis, underscoring the potential for diagnostic confusion with systemic inflammatory disease.
Shang Xiang, Dai-Ping Hua, Shih-Hung Yang et al.· Frontiers in Immunology· 0 citations
During disease progression, innovative sequential therapy with efgartigimod, an FcRn antagonist, was followed by the anti-CD20 monoclonal antibody rituximab (RTX) to reduce the risk of profound B-cell depletion, thereby demonstrating synergistic efficacy.
Jun-Tong Liu, Wen-Ping Zhu, Lan Gao et al.· Frontiers in Immunology· 1 citation
Background Anti-glutamic acid decarboxylase 65 (GAD65) antibody-associated neurological syndrome is a rare autoimmune disorder with heterogeneous clinical manifestations, including epilepsy and cerebellar ataxia. Standard treatment strategies remain limited. This report aimed to describe a rare case presenting with com...
Lu-Lu Xie, Junqin Zuo, Le Luo et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.